

Table 1. *Consensus Molecular Subtype Classification (CMS).*

Subtype	Biological findings	Clinical findings	Prognosis	Incidence
CMS 1 Immune	MSI high BRAF mutated Hypermutations (high TMB) Immune activation	Right sided Females Older age	Intermediate to poor survival	~ 14%
CMS 2 Canonical	CIN high ↑ EGFR activation MSS TP53 mutation ↑↑ WNT/MYC activation	Left sided	Good	~ 37%
CMS 3 Metabolic	CIN low KRAS mutation PI3K mutations Metabolic dysregulation		Intermediate	~ 13%
CMS 4 Mesenchymal	CIN high Notch3/VEGFR2 overexpression ↑ TGF-beta activation Stroma infiltration Angiogenesis	Younger age	Poor survival and worse relapse free survival	23%
Mixed	Intratumoral heterogeneity	Transition phenotype		13%